NASDAQ$IMVT
Immunovant Inc · Q4 2027 earnings
Q4 2027 earnings · · Before market open · Investor relations
Briefing
Immunovant Inc reported fiscal year 2026 results highlighting progress on IMVT-1402 while discontinuing batoclimab development.
In the fourth quarter of fiscal 2026, Immunovant advanced its clinical programs for IMVT-1402 across six indications including Graves' disease, rheumatoid arthritis, myasthenia gravis, CIDP, Sjogren's disease and cutaneous lupus erythematosus. The company maintained a strong cash position of $902.1 million to support ongoing development activities. No product revenue was generated as the company remains in the clinical stage with a net loss for the full fiscal year.
- Discontinued further development of batoclimab to fully focus resources on IMVT-1402 following Phase 3 results in thyroid eye disease.
- Initiated or continued potentially registrational trials for IMVT-1402 in multiple autoimmune indications with top-line data expected in 2027 and 2028.
- Reported positive open-label data from the difficult-to-treat rheumatoid arthritis trial showing strong ACR response rates at Week 16.
- Ended the fiscal year with $902.1 million in cash and cash equivalents providing runway through potential commercial launch in Graves' disease.
Headline financials
Revenue & EPS history
Immunovant · Revenue · Quarterly
$0
Forward guidance
The company expects to report top-line results from multiple IMVT-1402 trials in calendar year 2027 and 2028 while leveraging learnings from the batoclimab program.
Tailwinds
- Potential best-in-class IgG reduction profile for IMVT-1402
- Broad development program across six indications
- Strong balance sheet to fund operations through key milestones
Headwinds
- Clinical development and regulatory risks remain
- Competition from other FcRn inhibitors and alternative mechanisms
- No current product revenue with ongoing cash burn
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2027
+0.6%
Avg return
Earnings day
-1.7%
Avg return
5 days after
+2.2%
Avg return
30 days after
54%
15 / 28 earnings
Positive
+35.1%
Q4 2027
Best reaction
-34.6%
Q4 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2027 | +35.1% | — | — | |
| Q3 2026 | +12.4% | +7.8% | +10.8% | |
| Q2 2026 | +0.0% | +1.7% | +0.9% | |
| Q1 2026 | -4.5% | -1.6% | +4.8% | |
| Q4 2025 | -0.2% | +3.0% | +8.1% | |
| Q3 2025 | -9.6% | -14.1% | -11.1% | |
| Q2 2025 | -2.5% | -6.8% | -8.9% | |
| Q1 2025 | +1.0% | +9.4% | +25.9% | |
| Q4 2024 | -7.1% | -11.3% | -7.1% | |
| Q3 2024 | +4.0% | +4.6% | -10.4% | |
| Q2 2024 | -2.3% | +4.7% | +17.4% | |
| Q1 2024 | +7.4% | -1.9% | +11.5% | |
| Q4 2023 | +4.9% | -0.8% | -5.1% | |
| Q3 2023 | +0.7% | +2.0% | -6.9% | |
| Q2 2023 | +6.3% | -2.1% | +23.2% | |
| Q1 2023 | +19.4% | +24.7% | +23.7% | |
| Q4 2022 | -12.6% | -20.4% | +0.2% | |
| Q3 2022 | -2.7% | -2.5% | -8.8% | |
| Q2 2022 | +1.1% | -0.3% | -12.8% | |
| Q1 2022 | +4.4% | +1.7% | +15.5% | |
| Q4 2021 | -34.6% | -34.5% | -25.0% | |
| Q3 2021 | -13.6% | -18.6% | -25.0% | |
| Q2 2021 | +3.1% | +7.3% | -4.0% | |
| Q1 2021 | +3.7% | +2.3% | +40.2% | |
| Q4 2020 | -11.0% | -13.5% | -14.2% | |
| Q3 2020 | +12.5% | +13.2% | +1.3% | |
| Q2 2020 | +0.1% | +0.1% | +13.9% | |
| Q1 2020 | +0.0% | +0.0% | +0.6% | |
| Q3 2019 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro